Stock Price
107.57
Daily Change
0.42 0.39%
Monthly
-24.68%
Yearly
57.01%
Q2 Forecast
106.95

Insmed reported $256.46M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Cytokinetics USD 19.2M 1.44M Mar/2026
DBV Technologies USD 2.77M 33.21M Sep/2025
Gilead Sciences USD 5.52B 791M Mar/2026
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Insmed USD 256.46M 38.78M Mar/2026
Novartis USD 10.82B 694M Sep/2025
Regeneron Pharmaceuticals USD 2.94B 363.7M Mar/2026
Sarepta Therapeutics USD 621.34M 577.79M Mar/2026
Ultragenyx Pharmaceutical USD 106M 72M Mar/2026
Vertex Pharmaceuticals USD 2.6B 121.7M Mar/2026